EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Gastrointestinal malignancy is a leading cause of cancer mortality despite surgical and adjuvant treatments.
• Immunotherapy offers a novel approach by leveraging the immune system to eliminate cancer cells.
• Epithelial cell adhesion molecule (EpCAM) is differentially expressed on gastrointestinal tumors, making it a potential immunotherapy target.

Purpose of the Study:

• To review the role of EpCAM as a target for immunotherapy in gastrointestinal malignancies.
• To summarize the outcomes of clinical trials investigating EpCAM-based immunotherapies.
• To explore the future potential of EpCAM-mediated immune activation for cancer treatment.

Main Methods:

• Review of clinical trials involving various EpCAM-targeting agents, including naked antibodies, immunoconjugates, and vaccines.
• Analysis of data from a randomized controlled trial of murine IgG2a Edrecolomab in advanced colorectal carcinoma.
• Examination of ongoing clinical investigations of fully human and trifunctional antibodies.

Main Results:

• Clinical trials with EpCAM-targeting agents have yielded variable success.
• The murine IgG2a Edrecolomab showed a modest reduction in mortality and morbidity compared to 5FU and Levamisole in advanced colorectal cancer.
• Newer antibody designs are being evaluated for minimal residual disease and ascites treatment.

Conclusions:

• EpCAM is a viable target for immunotherapy in gastrointestinal cancers.
• While early trials show mixed results, EpCAM-based therapies hold future promise.
• Further development of EpCAM-mediated strategies may lead to effective immune activation against gastrointestinal tumors.